2
|
Feng Y, Ma PC. Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer. Cancer Discov 2012; 1:550-4. [PMID: 22586678 DOI: 10.1158/2159-8290.cd-11-0289] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The MET/hepatocyte growth factor (HGF) signaling pathway plays important roles in oncogenesis and tumor progression in a variety of human cancers. MET/HGF drives an invasive signaling program that can be dysregulated in human cancers through a number of activating mechanisms, including mutations, overexpression, amplification, alternative splicing, and HGF ligand-induced autocrine/paracrine loop signaling. As a testimony of MET-targeting therapeutics is beginning to come to clinical fruition, Catenacci and colleagues report the first case of durable complete response under an anti-MET receptor monoclonal antibody, MetMAb, in a patient with chemotherapy-refractory, advanced gastric cancer metastatic to the liver, found to have high MET gene polysomy and remarkably high serum HGF level. Serum and tissue studies also revealed predictive biomarkers for therapeutic response to MET inhibition.
Collapse
Affiliation(s)
- Yan Feng
- Department of Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
| | | |
Collapse
|
4
|
Cui JJ, McTigue M, Nambu M, Tran-Dubé M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P, Jalaie M, Goetz GH, Ryan K, Grodsky N, Deng YL, Parker M, Timofeevski S, Murray BW, Yamazaki S, Aguirre S, Li Q, Zou H, Christensen J. Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer. J Med Chem 2012; 55:8091-109. [DOI: 10.1021/jm300967g] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- J. Jean Cui
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Michele McTigue
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Mitchell Nambu
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Michelle Tran-Dubé
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Mason Pairish
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Hong Shen
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Lei Jia
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Hengmiao Cheng
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Jacqui Hoffman
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Phuong Le
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Mehran Jalaie
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Gilles H. Goetz
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Kevin Ryan
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Neil Grodsky
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Ya-li Deng
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Max Parker
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Sergei Timofeevski
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Brion W. Murray
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Shinji Yamazaki
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Shirley Aguirre
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Qiuhua Li
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - Helen Zou
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| | - James Christensen
- La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive,
San Diego, California 92121, United States
| |
Collapse
|
5
|
Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol 2012; 110:89-98. [PMID: 22821383 DOI: 10.1007/s11060-012-0938-9] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2012] [Accepted: 07/09/2012] [Indexed: 01/24/2023]
Abstract
Gliomas consist of multiple histologic and molecular subtypes with different clinical phenotypes and responsiveness to treatment. However, enrollment criteria for clinical trials still largely do not take into account these underlying molecular differences. We have incorporated a high-throughput tumor genotyping program based on the ABI SNaPshot platform as well as other molecular diagnostic tests into the standard evaluation of glioma patients in order to assess whether prospective molecular profiling would allow rational patient selection onto clinical trials. From 218 gliomas we prospectively collected SNaPshot genotyping data on 68 mutated loci from 15 key cancer genes along with data from clinical assays for gene amplification (EGFR, PDGFRA, MET), 1p/19q co-deletion and MGMT promoter methylation. SNaPshot mutations and focal gene amplifications were detected in 38.5 and 47.1 % of glioblastomas, respectively. Genetic alterations in EGFR, IDH1 and PIK3CA closely matched frequencies reported in recent studies. In addition, we identified events that are rare in gliomas although are known driver mutations in other cancer types, such as mutations of AKT1, BRAF and KRAS. Patients with genetic alterations that activate signaling pathways were enrolled onto genetically selective clinical trials for malignant glioma as well as for other solid cancers. High-throughput molecular profiling incorporated into the routine clinical evaluation of glioma patients may enable the rational selection of patients for targeted therapy clinical trials and thereby improve the likelihood that such trials succeed.
Collapse
|
7
|
Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011; 54:6342-63. [PMID: 21812414 DOI: 10.1021/jm2007613] [Citation(s) in RCA: 654] [Impact Index Per Article: 50.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.
Collapse
Affiliation(s)
- J Jean Cui
- La Jolla Laboratories, Pfizer Worldwide Research and Development, San Diego, California 92121, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|